Your browser doesn't support javascript.
loading
Technology-Assisted Self-Selection of Candidates for Nonprescription Statin Therapy.
Nissen, Steven E; Hutchinson, Howard G; Wang, Tracy Y; Ballantyne, Christie M; Travis, Sara; Morris, Melanie; Miller, William; Hynson, Jennifer; Wolski, Kathy; Ridker, Paul M.
Affiliation
  • Nissen SE; Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Ohio, USA; Cleveland Clinic Coordinating Center for Clinical Research, Cleveland Clinic, Cleveland Ohio, USA. Electronic address: nissens@ccf.org.
  • Hutchinson HG; AstraZeneca BioPharmaceuticals, Wilmington, Delaware, USA.
  • Wang TY; Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA.
  • Ballantyne CM; Baylor College of Medicine, Houston, Texas, USA.
  • Travis S; Concentrics Research, Indianapolis, Indiana, USA.
  • Morris M; AstraZeneca BioPharmaceuticals, Wilmington, Delaware, USA.
  • Miller W; Concentrics Research, Indianapolis, Indiana, USA.
  • Hynson J; Concentrics Research, Indianapolis, Indiana, USA.
  • Wolski K; Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Ohio, USA; Cleveland Clinic Coordinating Center for Clinical Research, Cleveland Clinic, Cleveland Ohio, USA.
  • Ridker PM; Center for Cardiovascular Disease Prevention, Harvard Medical School, Boston, Massachusetts, USA.
J Am Coll Cardiol ; 78(11): 1114-1123, 2021 09 14.
Article in En | MEDLINE | ID: mdl-34503680
ABSTRACT

BACKGROUND:

Although statins reduce cardiovascular morbidity and mortality, only about one-half of eligible patients receive treatment. Safe and appropriate consumer access to statins could have a significant positive public health impact.

OBJECTIVES:

This study compares the concordance between a participant and clinician assessment of eligibility for statin therapy using a technology-assisted approach.

METHODS:

A total of 500 participants, 83 with limited literacy, completed an at-home Web-based application to assess appropriateness for treatment with rosuvastatin 5 mg. The Web application is designed to assess eligibility for a moderate-intensity statin based on current guidelines and deny access to individuals with contraindications to rosuvastatin. Subsequently, participants visited a research site where clinicians, blinded to the information the participant entered, performed an independent Web application assessment. The Web application is programmed for 1 of 3 rosuvastatin treatment

outcomes:

"OK to use," "not right for you," or "ask a doctor." The primary endpoint was the percent of participants whose self-selected eligibility for nonprescription rosuvastatin was concordant with clinician assessment.

RESULTS:

For the primary endpoint, participant selection for statin therapy was concordant with clinician selection in 481 (96.2%) of 500 participants (95% confidence interval 94.1%-97.7%), of whom 23 (4.6%) were deemed appropriate and 458 (91.6%) were deemed inappropriate for treatment. Discordance was due to incorrect self-selection ("OK to use") in 3 cases, incorrect rejection ("not right for you") in 14 cases and an incorrect "ask a doctor" outcome in 2 cases.

CONCLUSIONS:

The use of a technology-assisted approach to consumer self-selection for statin therapy resulted in participant self-selection that showed substantial agreement with clinician selection.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Self Medication / Hydroxymethylglutaryl-CoA Reductase Inhibitors / Nonprescription Drugs / Rosuvastatin Calcium Type of study: Guideline Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: J Am Coll Cardiol Year: 2021 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Self Medication / Hydroxymethylglutaryl-CoA Reductase Inhibitors / Nonprescription Drugs / Rosuvastatin Calcium Type of study: Guideline Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: J Am Coll Cardiol Year: 2021 Document type: Article